Table 2.
Diagnostic power of succinate and ratios to differentiate between patients with and without SDHx PV in the presence (pre-OP) and absence (post-OP) of PPGL
| Tumor status | Matrix | Parametera | P valueb | AUC of ROC curvec |
|---|---|---|---|---|
| Pre-OP | Heparin plasma (n = 38) | Succinate | <.0001 | 0.907 (0.815, 0.999) |
| Succinate/Fumarate | <.0001 | 0.887 (0.786, 0.988) | ||
| Succinate/Malate | <.0001 | 0.907 (0.815, 0.999) | ||
| Succinate/Citrate | <.0001 | 0.910 (0.819, 1001) | ||
| Succinate/Asparagine | <.0001 | 0.849 (0.735, 0.963) | ||
| EDTA plasma (n = 18) | Succinate | .0050 | 0.900 (0.817, 0.983) | |
| Succinate/Fumarate | <.0001 | 0.900 (0.817, 0.983) | ||
| Succinate/Malate | .0255 | 0.775 (0.659, 0.891) | ||
| Succinate/Citrate | .0004 | 0.938 (0.871, 1.005) | ||
| Succinate/Asparagine | .0012 | 0.888 (0.801, 0.975) | ||
| Post-OP + asymptomatic carriers |
Heparin plasma (n = 38) | Succinate | .0111 | 0.699 (0.553, 0.845) |
| Succinate/Fumarate | <.0001 | 0.867 (0.759, 0.975) | ||
| Succinate/Malate | .0001 | 0.852 (0.739, 0.965) | ||
| Succinate/Citrate | <.0001 | 0.849 (0.735, 0.963) | ||
| Succinate/Asparagine | .0013 | 0.765 (0.630, 0.900) | ||
| EDTA plasma (n = 31) | Succinate | .0002 | 0.873 (0.781, 0.969) | |
| Succinate/Fumarate | <.0001 | 0.947 (0.885, 1.009) | ||
| Succinate/Malate | <.0001 | 0.956 (0.899, 1.013) | ||
| Succinate/Citrate | .0649 | 0.794 (0.682, 0.906) | ||
| Succinate/Asparagine | .3685 | 0.798 (0.687, 0.909) |
a Logistic regression analysis.
b Effect likelihood ratio test.
c Area under the receiver operating characteristic curve (95% CI).